Video

Ibrutinib-Rituximab and Venetoclax (IRV) Followed by Risk-Stratified R-HyperCVAD/MTX in Young Patients With Untreated Mantle Cell Lymphoma – Phase-II WINDOW-2 Trial

Author(s):

Michael Wang, MD

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Carrie L. Kitko, MD
Lori A. Leslie, MD
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Guenther Koehne, MD, PhD
Ibrahim Aldoss, MD
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University
May 31st 2024

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Craig Eckfeldt, MD, PhD, of the University of Minnesota
May 22nd 2024

Eckfeldt Looks Towards the Future of AML and MDS Care

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

WU-CART-007 for R/R T-ALL and T-LBL| Image Credit: © Dr_Microbe - stock.adobe.com
May 20th 2024

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD
May 17th 2024

State of the Science Summit - Hematologic Malignancies: Chaired by Veronika Bachanova, MD, PhD, and Jeffrey Miller, MD